Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 May;18(5):601-2.
doi: 10.1093/neuonc/now003. Epub 2016 Mar 14.

MicroRNAs provide a novel pathway toward combinatorial immune checkpoint blockade

Duane A Mitchell  1
Affiliations
Editorial

MicroRNAs provide a novel pathway toward combinatorial immune checkpoint blockade

Duane A Mitchell. Neuro Oncol. 2016 May.
No abstract available

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
(A) T cells within the tumor microenvironment and tumor draining lymph nodes encounter immune checkpoint inhibition through interactions with tumor cells, myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs). Depicted is the expression of programmed death ligand 1 (PD-L1) on tumor cells and myeloid-lineage suppressor cells engaging the PD-1 receptor on T cells leading to immune suppression. T cells expressing the inhibitory receptor, CTLA-4, also encounter their regulatory ligands expressed on myeloid cells within the tumor microenvironment and lymph nodes. (B) The delivery of miR-138 to T cells inhibits expression of the PD-1 receptor, thus rendering the T cell resistant to inhibition by PD-L1 on the surface of tumor cells, MDSCs, or TAMs. The miR-138 mediated downregulation of the PD-1 receptor may allow for effective maintenance of antitumor immunity in the treated host. MiR-138 delivery was shown to also downregulate expression of CTLA-4 and FoxP3 (not shown), leading to the stimulation of effective antitumor immunity in the GL261 glioma model.
See this image and copyright information in PMC

Comment on

  • MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.
    Wei J, Nduom EK, Kong LY, Hashimoto Y, Xu S, Gabrusiewicz K, Ling X, Huang N, Qiao W, Zhou S, Ivan C, Fuller GN, Gilbert MR, Overwijk W, Calin GA, Heimberger AB. Wei J, et al. Neuro Oncol. 2016 May;18(5):639-48. doi: 10.1093/neuonc/nov292. Epub 2015 Dec 11. Neuro Oncol. 2016. PMID: 26658052 Free PMC article.

References

    1. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013;19(19):5300–5309. - PubMed
    1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. - PMC - PubMed
    1. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. - PMC - PubMed
    1. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813. - PMC - PubMed
    1. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. - PMC - PubMed